Advertisement

Document › Details
CureVac AG. (11/20/19). "Press Release: CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference". Tübingen & Boston, MA.
![]() |
Region | New York, NY |
Country | United States (USA) | |
![]() |
Organisation | CureVac AG |
Group | CureVac (Group) | |
Organisation 2 | Solebury Trout | |
Group | PNC Financial Services (Group) | |
![]() |
Product | Piper Jaffray Annual Healthcare Conference 2019 New York |
Product 2 | mRNA-based drug | |
![]() |
Index term | CureVac–Piper Jaffray: investor conference, 201912 supply service CureVac presents at Piper Jaffray Healthcare Conference 2019 |
![]() |
Person | Menichella, Daniel L. (Dan) (Kaleido Biosciences 202010– CEO before CureVac + Bamboo Therapeutics + AGTC + Zyngenia) |
Person 2 | Hoffmann, Thomas (Trout Group 201412) | |
CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.
The company will also be holding one-on-one meetings. Interested parties can contact Thomas Hoffmann (thoffmann@soleburytrout.com) to schedule a meeting with CureVac representatives during the conference.
About CureVac AG
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years of expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million (€400 million) in equity investments, including significant investments from SAP founder Dietmar Hopp’s dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
***
Media Contact
Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com
Investor Relations Contact
Thomas Hoffmann
Solebury Trout
T: +1 646-378-2931
thoffmann@soleburytrout.com
Record changed: 2019-12-23 |
Advertisement

More documents for CureVac (Group)
- [1] CureVac AG. (8/4/20). "Press Release: CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer". Tübingen....
- [2] CureVac AG. (7/21/20). "Press Release: CureVac Raises a Total of USD 640 Million in Private Financing Round". Tübingen....
- [3] CureVac AG. (7/20/20). "Press Release: GSK and CureVac Announce Strategic mRNA Technology Collaboration"....
- [4] CureVac AG. (7/6/20). "Press Release: EIB and European Commission Provide CureVac with a €75 Million Financing for Vaccine development and Expansion of Manufacturing"....
- [5] CureVac AG (BMWI & Dievini Hopp Biotech Holding). (6/15/20). "Press Release: German Federal Government Invests 300 Million Euros in CureVac [This is a joint press release of the Federal Ministry of Economics and Energy and dievini Hopp Biotech holding]"....
- [6] CureVac AG. (3/16/20). "Press Release: CureVac Announces Leadership Update". Tübingen & Boston, MA....
- [7] CureVac AG. (3/15/20). "Press Release: CureVac Focuses on the Development of mRNA-based Coronavirus Vaccine to Protect People Worldwide. The Company Rejects Current Rumors of an Acquisition". Tübingen & Boston, MA....
- [8] dievini Hopp BioTech holding GmbH & Co. KG. (3/15/20). "Press Release: dievini nimmt Stellung zu Presseveröffentlichungen über ihre Beteiligungsgesellschaft". Walldorf....
- [9] CureVac AG. (3/11/20). "Press Release: Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG". Tübingen & Boston, MA....
- [10] CureVac AG. (3/2/20). "Press Release: CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force". Tübingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top